Evaluation of the effects of various gestagens on insulin sensitivity, using homeostatic model assessment, in postmenopausal women on hormone replacement therapy

Gynecological Endocrinology

Volumn 20, Issue 1, 2005, Pages 1-5

  Dansuk, Ramazan ^a,b   Unal, Orhan ^a   Karsidag, Yasemin Karageyim ^a   Turan, Cem ^a  

^a Kartal Lutfi Kirdar Education and Research Hospital   (Turkey)

^b NONE   (Turkey)

Author keywords

Gestagen; Hormone replacement therapy; Insulin sensitivity; Menopause

Indexed keywords

DYDROGESTERONE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRAFEM; GESTAGEN; INSULIN; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG EFFECT; EVALUATION; FEMALE; FOLLOW UP; HOMEOSTASIS; HOMEOSTATIC MODEL ASSESSMENT; HORMONE SUBSTITUTION; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ESTROGENS; FEMALE; HOMEOSTASIS; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; MODELS, BIOLOGICAL; POSTMENOPAUSE; PROGESTINS; PROSPECTIVE STUDIES;

EID: 15944389895     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590400020880     Document Type: Article

References (38)

1. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Am Med Assoc 1995; 273:199-208.
2. Kalkhoff RK, Jacobson M, Lemper D. Progesterone, pregnancy and the augmented plasma insulin response. J Clin Endocrinol Metab 1970;31:24-28.
3. Sumino H, Ichikawa S, Itoh H, Utsugi T, Ohyama Y, Umeda M, Nakamura T, Kanda T, Mizunuma H, Tomono S, et al. Hormone replacement therapy decreases insulin resistance and lipid metabolism in Japanese postmenopausal women with impaired and normal glucose tolerance. Horm Res 2003;60:134-142.
4. Godsland IF, Gangar K, Walton C, Cust MP, Whitehead MI, Wynn V, Stevenson JC. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846-853.
5. Costrini NV, Kalkhoff RK. Relative effects of pregnancy, estradiol, and progesterone on plasma insulin and pancreatic islet insulin secretion. J Clin Invest 1971;50:992-999.
6. Spellacy WN, Buhi WC, Birk SA. The effects of norgestrel on carbohydrate and lipid metabolism over one year. Am J Obstet Gynecol 1976;125:984-986.
7. Turtle S, Turkington VE. Effects of medroxyprogesterone acetate on carbohydrate metabolism. Obstet Gynecol 1974;43: 685-692.
8. Triusi RJ, Cowie CC, Harris MI. Hormone replacement therapy and glucose metabolism. Obstet Gynecol 2000;96: 665-670.
9. Bonora E, Targher G, Alberiche M, Bonadonna RCF, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
10. DeFronzo RA, Tobin JD, Andreas R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1970;237:E214-E223.
11. American Diabetes Association. Consensus Development Conference on insulin resistance. Diabetes Care 1998;21: 310-314.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
13. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB. Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992;74:1396-1400.
14. Crook D, Godsland IF, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 1997;104:298-304.
15. Lasco A, Alvaro S, Frisina N, Di Benedetto A, Denuzzo G, Cucinotta D. Long-term transdermal estrogen therapy improves lipid profile but not insulin resistance in healthy postmenopausal women. Diabetes Care 2000;23:422-424.
16. Lindenheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and attenuating effect of added progestin. Fertil Steril 1994;60:664-667.
17. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol 1994;84:987-995.
18. O'Sullivan AJ, Ho KK. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1995; 80:1783-1788.
19. Bailey CJ, Ahmed-Sorour H. Role of ovarian hormones in the long-term control of glucose homeostasis. Effects of insulin secretion. Diabetologia 1980;19:475-481.
20. Sutter-Dub MT, Dazey B, Hamdan E, Vergnaud MT. Progesterone and insulin-resistance: studies of progesterone action on glucose transport, lipogenesis and lipolysis in isolated fat cells of the female rat. Endocrinology 1981;88: 455-462.
21. Barrett-Connor E, Laakso M. Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis 1990;10:531-534.
22. Notelovitz M, Johnston M, Smith S, Kitchens C. Metabolic and hormonal effects of 25-mg and 50-mg 17β-estradiol implants in surgically menopausal women. Obstet Gynecol 1987;70:749-754.
23. Silfverstolpe G, Gustafson A, Samsioe G, Svanborg A. Lipid metabolic studies in oophorectomized women: effects induced by two different estrogens on serum lipids and lipoproteins. Gynecol Obstet Invest 1980;11:161-169.
24. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328:1069-1075.
25. Espeland MA, Hogan PE, Fineberg WE, Howard G, Schrott H, Waclawiw MA, Bush TL. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 1998;21:1589-1595.
26. Rushakoff RJ, Kalkhoff RK. Effects of pregnancy and sex steroid administration on skeletal muscle metabolism in the rat. Diabetes 1981;30:545-550.
27. Brussaard HE, Gevers Leuven JA, Frolich M, Kluft C, Krans HM. Short-term estrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997;40:843-849.
28. Manassiev NA, Godsland IF, Crook D, Proudler AJ, Whitehead MI, Stevenson JC. Effects of postmenopausal oestradiol and dydrogesterone therapy on lipoproteins and insulin sensitivity, secretion and elimination in hysterectomised women. Maturitas 2002;42:233-242.
29. Elkind-Hirsch KE, Sherman LD, Malinak R. Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab 1993;76:472-475.
30. Cagnacci A, Tuveri F, Cirillo R, Setteneri AM, Melis GB, Volpe A. The effect of transdermal 17β estradiol on glucose metabolism of postmenopausal women is evident during the oral but not the intravenous glucose administration. Maturitas 1997;28:163-167.
31. Spellacy WN, Buhi WC, Birk SA. The effect of estrogens on carbohydrate metabolism: glucose, insulin, and growth hormone studies on 171 women ingesting Premarin, mestranol, and ethinyl estradiol for six months. Am J Obstet Gynecol 1972;114:378-392.
32. De Cleyn K, Buytaert P, Coppens M. Carbohydrate metabolism during hormonal substitution therapy. Maturitas 1989;11:235-242.
33. Colacurci N, Zarcone R, Mollo A, Russo G, Passaro M, de Seta L, de Franciscis P. Effects of hormone replacement therapy on glucose metabolism. Panminerva Med 1998;40: 18-21.
34. Stevenson JC, Crook D, Godsland IF, Lees B, Whitehead MI. Oral versus transdermal hormone replacement therapy. Int J Fertil Menopausal Stud 1993;38:30-35.
35. Duncan AC, Lyall H, Roberts RN, Petrie Jr, MJ, Monaghan S, Hart DM, Connell JM, Lumsden MA. The effect of estradiol and combined estradiol-progestagen preparation on insulin sensitivity in healthy postmenopausal women. J Clin Endocrinol Metab 1999;84:2402-2407.
36. Kimmerle R, Heinemann L, Heise T, Bender R, Weyer C, Hirschberger S, Berger M. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 1999;6:36-42.
37. Spencer CP, Godsland IF, Cooper AJ, Ross D, Whitehead MI, Stevenson JC. Effects of oral and transdermal 17-β estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 2000;49:742-747.
38. Walker RJ, Lewis-Barned N, Sutherland WHF, Goulding A, Edwards EA, de Jong SA, Gold E, Walker HL. The effects of sequential combined oral 17-β estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomised single blind placebo-controlled study. Menopause 2001;8:27-32.